1. Home
  2. ADV vs AUPH Comparison

ADV vs AUPH Comparison

Compare ADV & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Advantage Solutions Inc.

ADV

Advantage Solutions Inc.

N/A

Current Price

$32.37

Market Cap

410.7M

ML Signal

N/A

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

N/A

Current Price

$16.26

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ADV
AUPH
Founded
1987
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
410.7M
2.2B
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
ADV
AUPH
Price
$32.37
$16.26
Analyst Decision
Buy
Buy
Analyst Count
2
7
Target Price
★ $42.50
$18.29
AVG Volume (30 Days)
58.1K
★ 860.8K
Earning Date
11-04-2026
10-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
★ 0.76
Revenue
★ $3,542,642,000.00
$283,055,000.00
Revenue This Year
$1.41
$16.65
Revenue Next Year
$1.27
$17.73
P/E Ratio
★ N/A
$21.82
Revenue Growth
N/A
★ N/A
52 Week Low
$0.49
$13.52
52 Week High
$47.45
$19.25

Technical Indicators

Market Signals
Indicator
ADV
AUPH
Relative Strength Index (RSI) 52.94 46.08
Support Level $27.51 $15.67
Resistance Level $34.29 $16.48
Average True Range (ATR) 3.49 0.55
MACD 0.40 -0.08
Stochastic Oscillator 40.22 19.84

Price Performance

Historical Comparison
ADV
AUPH

About ADV Advantage Solutions Inc.

Advantage Solutions Inc provides outsourced sales, marketing, merchandising, sampling, and retailer support services to consumer packaged goods manufacturers and retailers across North America. Its services are designed to support distribution, retail execution, shopper engagement, and private brand development across both physical and digital commerce environments. The company serves various clients across grocery, mass, club, retail pharmacy, convenience, and other channels. It operates through three reportable segments: Branded Services, Experiential Services, and Retailer Services. The majority of the revenue is derived from the Experiential Services segment, which provides in-store and digital sampling programs, demonstrations, and experiential events for manufacturers and retailers.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: